There has been much debate about combination therapy with Botox and anti-CGRP monoclonal antibodies including Aimovig, Ajovy, and Emgality. The two medications were not originally studied together leaving physicians uncertain about prescribing practices and many insurance companies unwilling to pay for both treatments. In Episode 68 of Heads UP, Dr. Lindsay Weitzel talks to Dr. Tim Smith about recent data on prescribing these two medications together. What does this mean for our community?